Market news
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor Global Healthcare Conference (September 9-11 in New York City) Format: Fireside Chat and 1x1 Investor MeetingsDate/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET H.C. Wainwright 28th Annual Gl
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.
Immuneering (IMRX) has an average rating of buy and mean price target of $18.17, according to analys
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates...
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This is the newest page. Registered accounts read further back.